Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07281703RecruitingPhase 1
Safety study of HY8931 in healthy adults
This study tests a new oral medication, HY8931, in healthy adults to see if it is safe and how the body processes it. You will be closely monitored during the trial.
BrisbaneAges 18–45 - NCT07282522Recruiting
Sensory and function in cervical disc herniation
This study looks at how cervical disc herniation affects sensation and daily function. If you have had neck pain for at least 3 months and have been diagnosed with cervical disc herniation, researchers want to compare your results to people without neck pain.
Iğdır, IğdirAges 18–65 - NCT07286747RecruitingPhase 2
Nicotinic Acid for Reversing Prediabetes
This trial tests whether a controlled-release form of nicotinic acid (a type of vitamin B3) can help people with prediabetes get their blood sugar back to normal. It also looks at how the treatment affects liver health.
BerlinAges 18–79 - NCT05644717RecruitingPhase 4
Testing erugliflozin for fatty liver and diabetes control
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Peshawar, KPKAges 18–65 - NCT07274813RecruitingEarly Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
ShanghaiAges 18–75 - NCT07271693RecruitingPhase 1
Safety study of a new medicine in healthy volunteers
This trial tests a new medicine called RO7806881 in healthy volunteers to see if it is safe, what dose is best, and how the body handles it. It is an early study that helps researchers decide if the drug should be tested in people with a disease.
ChristchurchAges 18–50 - NCT07276568Enrolling by invitationEarly Phase 1
Hepatocyte-like cell injection for small liver syndrome
This early-phase trial tests an injection of lab-grown liver cells into the stomach muscle to prevent or treat small-for-size syndrome, a condition where a partial liver graft is too small. It may also help people with acute or chronic liver failure.
Beijing, ProvinceAges Any age - NCT07264569RecruitingPhase 1/Phase 2
Testing a new drug for lung cancer that has spread to the brain or spinal fluid
This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.
Zhengzhou, HenanAges 18–70 - NCT07262281RecruitingPhase 1
Safety study of HY6725 in healthy adults
This trial tests a new drug called HY6725 in healthy volunteers to see if it is safe and how the body processes it. It may help pave the way for future treatments.
MelbourneAges 18–55 - NCT07269145RecruitingPhase 1
Testing TQB3122 capsules in advanced solid tumors
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07260305RecruitingPhase 1
Study of KGX101 alone or with Envafolimab for advanced solid tumors
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07262164RecruitingPhase 1
Testing VG2062 for advanced solid tumors
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
HebeiAges 18–75 - NCT07266402RecruitingPhase 3
Study of barzolvolimab for cold hives or skin writing
This trial tests an investigational drug called barzolvolimab for people with cold-induced hives or a condition where scratching causes raised lines (symptomatic dermographism) that aren't well controlled by antihistamines. The study compares the drug to a placebo to see if it reduces itching and hives.
Birmingham, AlabamaAges 18 years+ - NCT07267026RecruitingPhase 1
Safety study of the drug SK-09 in healthy adults
This trial tests a new medicine called SK-09 in healthy volunteers to see if it is safe and how the body processes it. The results will help decide the right dose for future studies.
Herston, QueenslandAges 18–55 - NCT07263139RecruitingPhase 2
Testing AGP100 for CPVT heart condition
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
OsloAges 18–75 - NCT07259889RecruitingPhase 1
CEL001 injection safety study for advanced solid tumors
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
BeijingAges 18 years+ - NCT07259538RecruitingPhase 1
Safety study of VVN432 nasal spray
This trial tests a nasal spray called VVN432 in healthy volunteers and people with chronic sinusitis. It checks if the spray is safe and how the body processes it.
BeijingAges 18–55 - NCT06291935RecruitingPhase 1
Gene therapy trial for retinitis pigmentosa with CNGA1 mutation
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
TübingenAges 18 years+ - NCT07258745RecruitingPhase 1
Comparing a risankizumab biosimilar to Skyrizi in healthy adults
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
Warsaw, WarszawaAges 18–55 - NCT07254481RecruitingPhase 1
Safety study of VB19055 in healthy volunteers
This trial tests a new drug (VB19055) in healthy volunteers to see how safe it is and how the body processes it. Participants will be watched closely and may help find the right dose for future studies.
HangzhouAges 18–50 - NCT07251166RecruitingPhase 1
Safety study of GenSci140 for advanced solid tumors
This trial tests a new drug, GenSci140, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shenyang, LiaoningAges 18–75 - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT07245771RecruitingPhase 1/Phase 2
Weight loss study testing a new drug alone or with tirzepatide
This trial tests an experimental drug called RN3161 to see if it helps with weight loss in people with overweight or obesity. It can be taken alone or with another weight-loss medication (tirzepatide).
Melbourne, VictoriaAges 18–65 - NCT07241910RecruitingPhase 1
Testing the safety of SYH2061 in healthy volunteers
This study tests a single dose of a new medication called SYH2061 to see if it is safe and how the body processes it. It is for healthy adults aged 18 to 55 who have had certain vaccines and are willing to follow study rules.
Hefei, AnhuiAges 18–55
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.